全文获取类型
收费全文 | 16965篇 |
免费 | 1346篇 |
国内免费 | 262篇 |
专业分类
耳鼻咽喉 | 657篇 |
儿科学 | 45篇 |
妇产科学 | 1745篇 |
基础医学 | 1039篇 |
口腔科学 | 362篇 |
临床医学 | 1328篇 |
内科学 | 1611篇 |
皮肤病学 | 252篇 |
神经病学 | 23篇 |
特种医学 | 719篇 |
外科学 | 3595篇 |
综合类 | 2461篇 |
预防医学 | 634篇 |
眼科学 | 37篇 |
药学 | 799篇 |
1篇 | |
中国医学 | 155篇 |
肿瘤学 | 3110篇 |
出版年
2024年 | 17篇 |
2023年 | 148篇 |
2022年 | 401篇 |
2021年 | 483篇 |
2020年 | 377篇 |
2019年 | 307篇 |
2018年 | 383篇 |
2017年 | 414篇 |
2016年 | 467篇 |
2015年 | 500篇 |
2014年 | 947篇 |
2013年 | 925篇 |
2012年 | 1085篇 |
2011年 | 1146篇 |
2010年 | 983篇 |
2009年 | 1029篇 |
2008年 | 974篇 |
2007年 | 1022篇 |
2006年 | 1000篇 |
2005年 | 886篇 |
2004年 | 734篇 |
2003年 | 663篇 |
2002年 | 544篇 |
2001年 | 596篇 |
2000年 | 475篇 |
1999年 | 369篇 |
1998年 | 281篇 |
1997年 | 259篇 |
1996年 | 204篇 |
1995年 | 170篇 |
1994年 | 132篇 |
1993年 | 77篇 |
1992年 | 53篇 |
1991年 | 40篇 |
1990年 | 52篇 |
1989年 | 41篇 |
1988年 | 40篇 |
1987年 | 30篇 |
1986年 | 26篇 |
1985年 | 50篇 |
1984年 | 33篇 |
1983年 | 28篇 |
1982年 | 38篇 |
1981年 | 34篇 |
1980年 | 44篇 |
1979年 | 29篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1972年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit 下载免费PDF全文
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献
2.
《Anais brasileiros de dermatologia》2019,94(1):42-46
BackgroundSkin cancer is a highly prevalent condition with a multifactorial etiology resulting from genetic alterations, environmental and lifestyle factors. In Brazil, among all malignant tumors, skin cancers have the highest incidences.ObjectiveTo retrospectively evaluate the incidence, prevalence and profile of basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma in Campos dos Goytacazes and region.Methods:In total, 2,207 histopathological reports of a local reference hospital were analyzed between January 2013 and December 2015, of which 306 corresponded to the neoplasms studied.Results:Of the 306 reports evaluated, 232 basal cell carcinomas (75.9%), 55 squamous cell carcinomas (18%) and 19 cutaneous melanomas (6.5%) were identified. The face was the most involved anatomical site (58.8%) and women (51%) were the most affected gender. The temporal analysis revealed a decrease in the overall incidence of 3.4% from 2013 to 2014 and 5.4% from 2014 to 2015. There was a 10.1% increase in basal cell carcinomas and 38% in melanomas in this period; however, there was a decrease in the number of squamous cell carcinomas of 14.8% during the studied years.Study limitations:Some samples of cutaneous fragments had no identification of the anatomical site of origin.Conclusion:Research that generates statistical data on cutaneous tumors produces epidemiological tools useful in the identification of risk groups and allows the adoption of more targeted and efficient future prevention measures. 相似文献
3.
目的以基因表达数据集资料为研究对象,分析BCAN基因在肾透明细胞癌中的表达情况以及对患者预后的影响。方法在Oncomine数据库中挖掘BCAN在肾透明细胞癌(ccRCC)中的表达情况。从TCGA数据库中获取ccRCC患者临床资料和目的基因的表达信息并进行统计分析。利用GEO数据库中GSE73731数据集的ccRCC样本进行基因富集分析。利用String数据库分析与BCAN相关的蛋白。结果BCAN低表达组的ccRCC患者在病理分期及T分期方面低于高表达组(P<0.001;P=0.001);N分期及M分期差异无统计学意义(P>0.05)。BCAN低表达组患者的总生存期优于高表达组(P=0.033)。BCAN基因高表达组的样本主要富集在KRAS信号通路。结论BCAN可以通过多种途径来促进肿瘤细胞的侵袭能力,有望成为ccRCC不良预后的重要生物标志物之一。 相似文献
4.
5.
6.
随着腹腔镜肝切除技术的发展与推广,腹腔镜肝切除中的一些难点,如术中出血的控制、解剖性肝切除、巨大肝癌切除、腹腔镜下联合肝脏分割与门静脉支结扎的二步肝切除术(ALPPS)等方面均基本解决。术中超声与荧光染色技术也得到普及。本文就上述问题做一概述,并对腹腔镜肝切除未来发展提出思路,以进一步推动我国腹腔镜肝切除的技术进步。 相似文献
7.
笔者根据现代临床子宫内膜的病理演变过程结合中医“异病同治”理念,提出“子宫内膜功能亢进性疾病”概念,涵盖5种常见的子宫内膜疾病:无排卵性异常子宫出血(Abnormal Uterine Bleeding Ovulatory dysfunction,AUB-O),子宫内膜息肉(Endometrial Polyp,EP),子宫内膜异位症(Endometriosis,EMs),子宫腺肌病(Adenomyosis,AM),子宫内膜癌(Endometrial Carcinoma,EC)。基于文献的汇总,分析得到此类疾病的子宫内膜病理演变与中医病因病机的关联性,为寻找关键通路、创新性治疗此类疾病提供了重要的参考方向,对深化中医妇科学常见疾病的共性病因病机提供了理论依据和探索思路。 相似文献
8.
目的:探讨二补助育汤对胚胎着床障碍模型小鼠子宫内膜形态及血管生成素-1(Ang-1)mRNA、血管内皮生长因子(VEGF)mRNA的表达和定位的影响。方法:24只ICR雌性小鼠随机分为空白组、模型组、戊酸雌二醇组、二补助育汤组,每组6只,用米非司酮建立胚胎着床障碍动物模型,各组给予相应药物灌胃,妊娠第5天处死小鼠后,检测各组妊娠率、平均着床位点数、子宫内膜Ang-1和VEGF mRNA表达量及其蛋白定位。结果:模型组小鼠平均胚胎着床位点数、Ang-1 mRNA、VEGF mRNA表达量明显低于空白组(均P<0.05);与模型组比较,二补助育汤组平均胚胎着床位点数、Ang-1 mRNA、VEGF mRNA表达量显著提高(均P<0.05)。结论:二补助育汤可提高子宫内膜Ang-1和VEGF蛋白表达量,促进子宫内膜血管生成,从而提高子宫内膜容受性。 相似文献
9.
目的 探讨甲状腺功能减退与子宫内膜癌(EC)的关系及EC患者癌组织分化程度和雌激素受体(ER)、孕激素受体(PR)的表达与甲状腺功能之间的关系。方法 选取2015年1月—2018年7月我院收治的EC患者113例,同时随机选取年龄与EC组相匹配的此段时间内我院健康体检的妇女156例作为对照组,检测血清促甲状腺激素(TSH)、甲状腺激素(FT4)。比较两组间甲状腺功能减退的患病率,并利用免疫组织化学法测定EC患者手术切除标本的癌组织中ER、PR的表达,分析EC患者癌组织分化程度及癌组织中ER、PR的表达与甲状腺功能之间的相关性。结果 EC组甲状腺功能减退的患病率较对照组高(P<0.000)。低分化EC患者的TSH高于中分化EC患者(P=0.025)。EC手术切除标本的癌组织中ER、PR阳性与阴性患者的TSH、FT4差异无统计学意义(P>0.05)。结论 甲状腺功能减退与EC具有相关性。 相似文献
10.
Takashi Murakami Naoto Sakamoto Akihito Nagahara 《Journal of gastroenterology and hepatology》2019,34(10):1685-1695
Sessile serrated adenoma/polyps (SSA/Ps) are early precursor lesions in the serrated neoplasia pathway, which results in BRAF‐mutated colorectal carcinomas with not only high levels of microsatellite instability but also microsatellite stable. SSA/Ps with advanced histology, including cytological dysplasia or minimally invasive carcinomas, are important lesions because SSA/Ps are considered major contributors to “interval cancers” and these lesions can rapidly become dysplastic or invasive carcinomas. Clinicopathologically, SSA/Ps with dysplasia or invasive carcinoma were associated with advanced age, female sex, and proximal colon. Although SSA/Ps with submucosal invasive carcinoma were smaller and invaded less deeply into the submucosal layer than conventional tubular adenomas with submucosal invasive carcinoma, SSA/Ps with submucosal invasive carcinoma frequently had a mucinous component and exhibited a higher potential for lymphatic invasion and lymph node metastasis. In an SSA/P series, endoscopic characteristics, including (semi)pedunculated morphology, double elevation, central depression, and reddishness, may help accurately diagnose SSA/Ps with advanced histology. Removal of SSA/Ps with dysplasia or invasive carcinoma was recommended. Endoscopic treatment such as endoscopic mucosal resection or endoscopic submucosal dissection is useful for those lesions. However, surgical resection with lymph node dissection might be indicated when SSA/Ps with invasive carcinoma are endoscopically suspected, because these have the high risk of lymph node metastasis. Greater awareness may promote further research into improving the detection, recognition, and complete resection rates of SSA/Ps with dysplasia or invasive carcinoma and reduce the interval cancer rates. 相似文献